Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Rick E Winningham
|
| gptkbp:collaboratedWith |
GlaxoSmithKline
|
| gptkbp:countryOfOperation |
gptkb:Cayman_Islands
|
| gptkbp:focusesOn |
infectious diseases
respiratory diseases gastrointestinal disorders |
| gptkbp:founded |
2013
|
| gptkbp:headquartersLocation |
gptkb:George_Town,_Cayman_Islands
|
| https://www.w3.org/2000/01/rdf-schema#label |
Theravance Biopharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:numberOfEmployees |
approximately 300 (2023)
|
| gptkbp:originatedIn |
Theravance, Inc.
|
| gptkbp:product |
Vibativ
Yupelri |
| gptkbp:researchInterest |
small molecule medicines
lung diseases |
| gptkbp:spinOff |
Theravance, Inc.
|
| gptkbp:tradedOn |
NASDAQ: TBPH
|
| gptkbp:website |
https://www.theravance.com/
|
| gptkbp:bfsParent |
gptkb:Fred_Hassan
gptkb:Mary_Jo_Rolli |
| gptkbp:bfsLayer |
7
|